4,273 Shares in Laboratory Co. of America Holdings (NYSE:LH) Bought by Alexander Randolph Advisory Inc.

Alexander Randolph Advisory Inc. acquired a new stake in Laboratory Co. of America Holdings (NYSE:LH) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 4,273 shares of the medical research company’s stock, valued at approximately $955,000. Laboratory Co. of America accounts for approximately 0.8% of Alexander Randolph Advisory Inc.’s holdings, making the stock its 29th biggest holding.

A number of other large investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Laboratory Co. of America by 2.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 114,488 shares of the medical research company’s stock valued at $25,012,000 after buying an additional 2,934 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Laboratory Co. of America by 17.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 101,019 shares of the medical research company’s stock worth $22,069,000 after purchasing an additional 14,708 shares in the last quarter. Great Valley Advisor Group Inc. acquired a new position in shares of Laboratory Co. of America during the 2nd quarter worth $473,000. CANADA LIFE ASSURANCE Co increased its holdings in shares of Laboratory Co. of America by 18.9% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 150,046 shares of the medical research company’s stock valued at $32,802,000 after purchasing an additional 23,860 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Laboratory Co. of America by 9.5% during the first quarter. Sei Investments Co. now owns 131,756 shares of the medical research company’s stock worth $28,784,000 after buying an additional 11,441 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Up 0.5 %

LH stock traded up $1.28 during midday trading on Wednesday, hitting $245.54. The stock had a trading volume of 121,796 shares, compared to its average volume of 664,670. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $247.99. The firm has a market cap of $20.54 billion, a PE ratio of 47.25, a price-to-earnings-growth ratio of 2.01 and a beta of 1.05. The company’s 50-day moving average price is $223.60 and its 200 day moving average price is $215.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating the consensus estimate of $3.48 by $0.02. The firm had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a return on equity of 15.27% and a net margin of 3.43%. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.38 earnings per share. On average, equities research analysts predict that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio is currently 55.71%.

Insider Buying and Selling at Laboratory Co. of America

In other news, CFO Glenn A. Eisenberg sold 15,000 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $223.99, for a total transaction of $3,359,850.00. Following the completion of the sale, the chief financial officer now directly owns 31,289 shares in the company, valued at $7,008,423.11. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Laboratory Co. of America news, CEO Adam H. Schechter sold 6,189 shares of Laboratory Co. of America stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $243.47, for a total transaction of $1,506,835.83. Following the transaction, the chief executive officer now directly owns 87,441 shares of the company’s stock, valued at $21,289,260.27. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Glenn A. Eisenberg sold 15,000 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $223.99, for a total transaction of $3,359,850.00. Following the completion of the sale, the chief financial officer now directly owns 31,289 shares of the company’s stock, valued at $7,008,423.11. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,189 shares of company stock worth $5,550,786 in the last quarter. 0.85% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have issued reports on LH. Evercore ISI dropped their target price on shares of Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating for the company in a report on Tuesday, September 24th. Truist Financial boosted their target price on Laboratory Co. of America from $255.00 to $275.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. HSBC upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a research report on Wednesday, October 30th. Hsbc Global Res upgraded shares of Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Bank of America raised their target price on shares of Laboratory Co. of America from $240.00 to $260.00 and gave the company a “buy” rating in a report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Laboratory Co. of America currently has a consensus rating of “Moderate Buy” and an average price target of $255.92.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.